Ascenta Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to discovering and developing new medicines to stop cancer. Our core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Ascenta has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The programs for AT-101 and AT-406 are currently in clinical development with trials open in the US and Europe. In addition, we have entered into collaborations with Sanofi Aventis, Ascentage Pharma Group Corporation, and the Leukemia and Lymphoma Society to accelerate global development of all three programs. Our development team has broad expertise in oncology and is focused exclusively on addressing the unique obstacles and complex challenges cancer brings to drug development.